


2

Docket No. UF-260XC1
Serial No. 09/997,447In the Claims

Claim 1-5 (Cancelled).

Claim 6 (Currently Amended): A method for promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising an anti-convulsant agent and a carrier to an individual.

Claim 7 (Currently Amended): The method according to claim 6, wherein said anti-convulsant agent is of the formula:




(Formula I)

wherein

X₁ is CH₂ or oxygen;R₁ is hydrogen or alkyl; and

R₂, R₃, R₄, and R₅ are independently hydrogen or lower alkyl and, when X₁ is CH₂, R₄ and R₅ can combine to form a benzene ring and when X₁ is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the following formula:



wherein R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

J:\UF\260XC1\Amend-Resp\SuppResp.doc\DNB/ssa

3

Docket No. UF-260XC1
Serial No. 09/997,447


Claim 8 (Currently Amended): The method according to claim 6, wherein said composition comprises a salve, ointment, aerosol, cosmetic, liquid, tablet, powder, capsule, or bioadhesive.

Claim 9 (Original): The method according to claim 6, wherein said composition is administered as a component of a bandage, transdermal patch, wound dressing, cosmetic, or bioadhesive.

Claim 10 (Original): The method according to claim 8, wherein said composition is a component of a bandage, wound covering, or wound dressing.

Claims 11-32 (Cancelled).

Claim 33 (New): A method of treating dermatological injury or tissue damage comprising the administration, to an individual, of a therapeutically effective amount of a composition comprising a carrier and an anticonvulsant agent of the formula:



(Formula I)

wherein


X₁ is CH₂ or oxygen;

R₁ is hydrogen or alkyl; and

4

Docket No. UF-260XC1
Serial No. 09/997,447

R₂, R₃, R₄, and R₅ are independently hydrogen or lower alkyl and when X₁ is CH₂, R₄ and R₅ can combine to form a benzene ring and when X₁ is oxygen, and R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the following formula:



wherein R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

Claim 34 (New): The method according to claim 33, wherein said composition is topically administered.

Claim 35 (New): The method according to claim 33, wherein said composition is orally administered.

Claim 36 (New): The method according to claim 33, wherein said composition is parenterally administered.

Claim 37 (New): The method according to claim 33, wherein said composition is administered via injection.

Claim 38 (New): The method according to claim 33, wherein said composition comprises a salve, ointment, aerosol, cosmetic, liquid, tablet, powder, capsule, or bioadhesive.

5

Docket No. UF-260XC1
Serial No. 09/997,447

Claim 39 (New): The method according to claim 33, wherein said composition is administered as a component of a bandage, transdermal patch, wound dressing, cosmetic, or bioadhesive.

Claim 40 (New): The method according to claim 6, wherein said composition is topically administered.

Claim 41 (New): The method according to claim 6, wherein said composition is orally administered.

Claim 42 (New): The method according to claim 6, wherein said composition is parenterally administered.

Claim 43 (New): The method according to claim 6, wherein said composition is administered via injection.

Claim 44 (New): The method according to claim 7, wherein said compound is topiramate.

Claim 45 (New): The method according to claim 33, wherein said compound is topiramate.